The reiterated Buy rating and maintained $66 price target by HC Wainwright & Co. analyst Raghuram Selvaraju on BioXcel Therapeutics (BTAI) is a positive signal for the stock. This reaffirms the analyst's confidence in the company's potential, which could lead to an increase in investor interest and a short-term positive impact on the stock price.